-
1.发明申请Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determining single nucleotide polymorphisms 审中-公开通过确定单核苷酸多态性识别阿尔茨海默病的遗传风险和评估治疗方法公开(公告)号：US20050177881A1
公开(公告)日：2005-08-11
申请号：US10497590
申请日：2002-12-03
IPC分类号： A01K67/027 , A61K45/00 , A61K49/00 , A61P25/28 , C07K16/40 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/48 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： Based on the unexpected identification of single nucleotide polymorphisms in the LIPA gene as novel genetic risk factors that link cholesterol metabolism to Alzheimer's disease, the present invention provides a method of diagnosing or prognosticating Alzheimer's disease, or determining the propensity or predisposition of a subject to develop Alzheimer's disease. The method comprises detecting the presence or absence of a variation in the LIPA gene which encodes the enzyme acid cholesteryl ester hydrolase. Furthermore, the invention provides methods of diagnosing Alzheimer's disease by using the CH25H gene and/or the LIPA gene and their corresponding gene products.
摘要翻译： 基于LIPA基因中单核苷酸多态性的意想不到的鉴定，将胆固醇代谢与阿尔茨海默氏病联系起来的新遗传风险因素，本发明提供了一种诊断或预测阿尔茨海默氏病或确定受试者发展倾向或倾向的方法 阿尔茨海默氏病。 该方法包括检测编码酶酸性胆固醇酯水解酶的LIPA基因中存在或不存在变异。 此外，本发明提供了通过使用CH25H基因和/或LIPA基因及其相应的基因产物来诊断阿尔茨海默氏病的方法。
-
公开(公告)号：US20080108568A1
公开(公告)日：2008-05-08
申请号：US11837326
申请日：2007-08-10
IPC分类号： A61K31/551 , A61K31/167 , A61K31/472 , A61K31/4985 , A61K38/16 , C12Q1/68 , A61P25/28 , A61K38/10 , A61K31/505 , A61K31/519
CPC分类号： A61K31/167 , A61K31/21 , A61K31/22 , A61K31/295 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/47 , A61K31/4985 , A61K31/505 , A61K31/519 , A61K31/53 , A61K31/551 , A61K38/10 , A61K38/16 , A61K45/06 , A61K2300/00
摘要： The present invention provides a method for improving learning and memory in a subject by administering a therapeutically effective amount of a compound of Formula I: or of Formula II: or of Formula III: (R1)x-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys-Leu —(R2)y (III).
摘要翻译： 本发明提供了一种通过施用治疗有效量的式I化合物或式II化合物或式III化合物来改善受试者的学习和记忆的方法：<？在线公式描述=“在线 （R 1）X-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg -Lys-Leu - （R 2）3（III）。 <？in-line-formula description =“In-line Formulas”end =“tail”？>
-
3.发明申请Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determining cyp46 genotype 审中-公开通过确定cyp46基因型识别阿尔茨海默病的遗传风险和评估治疗方法公开(公告)号：US20050048492A1
公开(公告)日：2005-03-03
申请号：US10495261
申请日：2002-03-01
IPC分类号： C12Q1/68 , G01N33/573 , G01N33/68 , G01N33/92
CPC分类号： G01N33/573 , G01N33/6896 , G01N33/92 , G01N2800/2821 , G01N2800/52
摘要： Based on the unexpected identification of a CYP46 gene polymorphism as a novel genetic risk factor that links cholesterol metabolism to Alzheimer's disease, the present invention provides a method of diagnosing or prognosticating Alzheimer's disease, or determining the propensity or predisposition of a subject to develop Alzheimer's disease. The method comprises detecting the presence or absence of a variation in the CYP46 gene which encodes the enzyme cholesterol 24-hydroxylase.
摘要翻译： 基于CYP46基因多态性的意外识别作为将胆固醇代谢与阿尔茨海默氏病联系起来的新型遗传风险因子，本发明提供了诊断或预测阿尔茨海默氏病或确定受试者发展为阿尔茨海默氏病的倾向或倾向的方法 。 该方法包括检测编码酶胆固醇24-羟化酶的CYP46基因的变异的存在或不存在。
-
公开(公告)号：US07993836B2
公开(公告)日：2011-08-09
申请号：US12162262
申请日：2007-01-26
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present invention relates to DNA sequences associated with human memory performance. It also provides methods for (i) screening for diseases and pathological conditions affecting human memory, (ii) identifying agents useful for treatment of diseases and pathological conditions affecting human memory, and (iii) agents and compositions useful for treatment of diseases and pathological conditions affecting human memory.
摘要翻译： 本发明涉及与人类记忆性能相关的DNA序列。 它还提供了（i）筛选影响人类记忆的疾病和病理状况的方法，（ii）鉴定可用于治疗影响人类记忆的疾病和病理状况的药剂，和（iii）可用于治疗疾病和病理状况的药剂和组合物 影响人的记忆。
-
公开(公告)号：US20090227500A1
公开(公告)日：2009-09-10
申请号：US12162262
申请日：2007-01-26
IPC分类号： A61K38/16 , C12Q1/68 , A61K31/7088 , C07K14/00
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present invention relates to DNA sequences associated with human memory performance. It also provides methods for (i) screening for diseases and pathological conditions affecting human memory, (ii) identifying agents useful for treatment of diseases and pathological conditions affecting human memory, and (iii) agents and compositions useful for treatment of diseases and pathological conditions affecting human memory.
摘要翻译： 本发明涉及与人类记忆性能相关的DNA序列。 它还提供了（i）筛选影响人类记忆的疾病和病理状况的方法，（ii）鉴定可用于治疗影响人类记忆的疾病和病理状况的药剂，和（iii）可用于治疗疾病和病理状况的药剂和组合物 影响人的记忆。
-
公开(公告)号：US08426130B2
公开(公告)日：2013-04-23
申请号：US12148728
申请日：2008-04-21
申请人： Dietrich A. Stephan , Eric M. Reiman , Jennifer Webster , Andreas Papassotiropoulos , Pamela Heward
发明人： Dietrich A. Stephan , Eric M. Reiman , Jennifer Webster , Christopher B. Heward , Andreas Papassotiropoulos
CPC分类号： C12Q1/6883 , A61K31/7088 , A61K31/711 , A61K31/713 , C12N15/113 , C12N2310/14 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.
-
7.发明申请METHODS OF DIAGNOSING ALZHEIMER'S DISEASE AND MARKERS IDENTIFIED BY SET ASSOCIATION 审中-公开诊断阿尔茨海默病的方法和设定协会标识的标记公开(公告)号：US20090260092A1
公开(公告)日：2009-10-15
申请号：US12487608
申请日：2009-06-18
申请人： Dietrich A. STEPHAN , Eric M. Reiman , Jennifer Webster , Christopher B. Heward , Pamela Heward , Andreas Papassotiropoulos
发明人： Dietrich A. STEPHAN , Eric M. Reiman , Jennifer Webster , Christopher B. Heward , Pamela Heward , Andreas Papassotiropoulos
IPC分类号： A01K67/027 , C12Q1/68 , G01N33/53 , C40B30/04 , C07H21/04
CPC分类号： C12Q1/6883 , A61K31/7088 , A61K31/711 , A61K31/713 , C12N15/113 , C12N2310/14 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.
摘要翻译： 本公开涉及用于诊断和筛选迟发性阿尔茨海默氏病（LOAD）的遗传标记和方法。 因此，本公开内容包括其中数量位于GRB2相关结合蛋白2（GAB2）基因内的单核苷酸多态性（SNP）以及与其他基因相关的其他标志物的全基因组关联分析。 该公开内容鉴定了GAB2基因内的两种新型单体型，即LOAD风险增强型和LOAD风险降低型单元型。 这些单元型与APOE等位基因组合差异地修饰LOAD风险。 进一步包括降低与LOAD相关的细胞的恶化的治疗方法和试剂。
-
8.发明申请Methods of diagnosing alzheimer's disease and markers identified by set association 有权诊断阿尔茨海默病的方法和通过设定关联识别的标志物公开(公告)号：US20090249498A1
公开(公告)日：2009-10-01
申请号：US12148728
申请日：2008-04-21
申请人： Dietrich A. Stephan , Eric M. Reiman , Jennifer Webster , Christopher B. Heward , Pamela Heward , Andreas Papassotiropoulos
发明人： Dietrich A. Stephan , Eric M. Reiman , Jennifer Webster , Christopher B. Heward , Pamela Heward , Andreas Papassotiropoulos
IPC分类号： C12Q1/68 , C07H21/04 , A01K67/027 , G01N33/00
CPC分类号： C12Q1/6883 , A61K31/7088 , A61K31/711 , A61K31/713 , C12N15/113 , C12N2310/14 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.
摘要翻译： 本公开涉及用于诊断和筛选迟发性阿尔茨海默氏病（LOAD）的遗传标记和方法。 因此，本公开内容包括其中数量位于GRB2相关结合蛋白2（GAB2）基因内的单核苷酸多态性（SNP）以及与其他基因相关的其他标志物的全基因组关联分析。 该公开内容鉴定了GAB2基因内的两种新型单倍型，即LOAD风险增强和LOAD风险降低单体型。 这些单元型与APOE等位基因组合差异地修饰LOAD风险。 进一步包括降低与LOAD相关的细胞的恶化的治疗方法和试剂。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.018 秒)
